Skip to main content

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.

Publication ,  Journal Article
Saad, ED; Kraut, EH; Hoff, PM; Moore, DF; Jones, D; Pazdur, R; Abbruzzese, JL
Published in: Am J Clin Oncol
October 2002

Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We conducted a phase II study of dolastatin-10 in patients with advanced colorectal cancer and no prior chemotherapy for metastatic disease. Fourteen patients received doses ranging from 300 microg/m(2) to 450 microg/m(2) as an intravenous push every 21 days. There were no major objective responses. Toxicity was mainly hematologic, with grade III or IV granulocytopenia occurring in 9 of 42 treatment courses. Other toxic effects were generally mild. Dolastatin-10 lacks clinically significant activity in advanced colorectal cancer when used in this dose and schedule.

Duke Scholars

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

October 2002

Volume

25

Issue

5

Start / End Page

451 / 453

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Oligopeptides
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Administration Schedule
  • Depsipeptides
  • Colorectal Neoplasms
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Saad, E. D., Kraut, E. H., Hoff, P. M., Moore, D. F., Jones, D., Pazdur, R., & Abbruzzese, J. L. (2002). Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol, 25(5), 451–453. https://doi.org/10.1097/00000421-200210000-00005
Saad, Everardo D., Eric H. Kraut, Paulo M. Hoff, Dennis F. Moore, Donnah Jones, Richard Pazdur, and James L. Abbruzzese. “Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.Am J Clin Oncol 25, no. 5 (October 2002): 451–53. https://doi.org/10.1097/00000421-200210000-00005.
Saad ED, Kraut EH, Hoff PM, Moore DF, Jones D, Pazdur R, et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol. 2002 Oct;25(5):451–3.
Saad, Everardo D., et al. “Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.Am J Clin Oncol, vol. 25, no. 5, Oct. 2002, pp. 451–53. Pubmed, doi:10.1097/00000421-200210000-00005.
Saad ED, Kraut EH, Hoff PM, Moore DF, Jones D, Pazdur R, Abbruzzese JL. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol. 2002 Oct;25(5):451–453.

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

October 2002

Volume

25

Issue

5

Start / End Page

451 / 453

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Oligopeptides
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Administration Schedule
  • Depsipeptides
  • Colorectal Neoplasms
  • Antineoplastic Agents